Kinase Inhibitor Ibrutinib to Prevent Cytokine-release Syndrome After Anti-CD19 Chimeric Antigen Receptor T Cells for B-cell Neoplasms

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2016 Sep 29

PMID 27677739

Citations 74

Authors

M Ruella

S S Kenderian

O Shestova

M Klichinsky

J J Melenhorst

M A Wasik

S F Lacey

C H June

S Gill

Affiliations

Soon will be listed here.

Citing Articles

Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review.

Miklos D, Riedell P, Bokun A, Chavez J, Schuster S Target Oncol. 2025; .

PMID: 40035913 DOI: 10.1007/s11523-025-01133-9.

Novel strategies to manage CAR-T cell toxicity.

Mulvey A, Trueb L, Coukos G, Arber C Nat Rev Drug Discov. 2025; .

PMID: 39901030 DOI: 10.1038/s41573-024-01100-5.

Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors.

Khan S, Choi Y, Veena M, Lee J, Shin D Front Immunol. 2025; 15():1489827.

PMID: 39835140 PMC: 11743624. DOI: 10.3389/fimmu.2024.1489827.

Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy.

Hughes A, Teachey D, Diorio C Semin Immunopathol. 2024; 46(3-4):5.

PMID: 39012374 PMC: 11252192. DOI: 10.1007/s00281-024-01013-w.

CAR-T Cells in Chronic Lymphocytic Leukemia.

Testa U, Pelosi E, Castelli G, Fresa A, Laurenti L Mediterr J Hematol Infect Dis. 2024; 16(1):e2024045.

PMID: 38882451 PMC: 11178044. DOI: 10.4084/MJHID.2024.045.

References

Fraietta J, Beckwith K, Patel P, Ruella M, Zheng Z, Barrett D . Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016; 127(9):1117-27. PMC: 4778162. DOI: 10.1182/blood-2015-11-679134. View

Lee D, Gardner R, Porter D, Louis C, Ahmed N, Jensen M . Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-95. PMC: 4093680. DOI: 10.1182/blood-2014-05-552729. View

Wang M, Rule S, Martin P, Goy A, Auer R, Kahl B . Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013; 369(6):507-16. PMC: 4513941. DOI: 10.1056/NEJMoa1306220. View

Ruella M, Kenderian S, Shestova O, Fraietta J, Qayyum S, Zhang Q . The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. Clin Cancer Res. 2016; 22(11):2684-96. DOI: 10.1158/1078-0432.CCR-15-1527. View

Kohrt H, Sagiv-Barfi I, Rafiq S, Herman S, Butchar J, Cheney C . Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood. 2014; 123(12):1957-60. PMC: 3962169. DOI: 10.1182/blood-2014-01-547869. View

Maude S, Frey N, Shaw P, Aplenc R, Barrett D, Bunin N . Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-17. PMC: 4267531. DOI: 10.1056/NEJMoa1407222. View

Davila M, Riviere I, Wang X, Bartido S, Park J, Curran K . Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014; 6(224):224ra25. PMC: 4684949. DOI: 10.1126/scitranslmed.3008226. View

Byrd J, Furman R, Coutre S, Flinn I, Burger J, Blum K . Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013; 369(1):32-42. PMC: 3772525. DOI: 10.1056/NEJMoa1215637. View

Sagiv-Barfi I, Kohrt H, Czerwinski D, Ng P, Chang B, Levy R . Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci U S A. 2015; 112(9):E966-72. PMC: 4352777. DOI: 10.1073/pnas.1500712112. View

10.

Teachey D, Lacey S, Shaw P, Melenhorst J, Maude S, Frey N . Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. Cancer Discov. 2016; 6(6):664-79. PMC: 5448406. DOI: 10.1158/2159-8290.CD-16-0040. View

11.

Maude S, Barrett D, Teachey D, Grupp S . Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014; 20(2):119-22. PMC: 4119809. DOI: 10.1097/PPO.0000000000000035. View

12.

Ruella M, June C . Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You. Curr Hematol Malig Rep. 2016; 11(5):368-84. DOI: 10.1007/s11899-016-0336-z. View

13.

Kalos M, Levine B, Porter D, Katz S, Grupp S, Bagg A . T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011; 3(95):95ra73. PMC: 3393096. DOI: 10.1126/scitranslmed.3002842. View

14.

Dubovsky J, Beckwith K, Natarajan G, Woyach J, Jaglowski S, Zhong Y . Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013; 122(15):2539-49. PMC: 3795457. DOI: 10.1182/blood-2013-06-507947. View